FRANKFURT, March 20 (Reuters) - Novartis said on Friday it agreed to acquire breast cancer drug candidate SNV4818 from Synnovation Therapeutics for $2 billion upfront and up to $1 billion contingent ...

Recent advances in drug discovery research have led to the development of numerous drug candidate compounds with high ...

Novartis has reached an agreement to buy a PI3K-targeting drug for breast cancer from Synnovation Therapeutics, paying a hefty $2 billion upfront for the asset, which is in phase 1/2 testing. The deal ...

SNV4818 is an oral treatment currently being evaluated in an early and mid-stage study for breast cancer and other advanced solid tumors.

A triple drug approach that blocks the KRAS pathway at three points eliminated pancreatic tumors and prevented resistance in ...

A growing body of research has examined the IRA’s implications for pharmaceutical innovation. Much of this literature has focused on the potential impact on the number of new drug launches, 5, 6 but ...

Recent advances in drug discovery research have led to the development of numerous drug candidate compounds with high therapeutic efficacy.

Recent data suggests people taking GLP-1 drugs may develop colorectal cancer less often than those taking aspirin, a ...

FRANKFURT, March 20 (Reuters) - Swiss drugmaker Novartis on Friday agreed to buy a breast cancer drug candidate for up to $3 billion from U.S. biotech firm Synnovation Therapeutics, adding a targeted ...